NASDAQ:MBX MBX Biosciences Q3 2025 Earnings Results & Report $53.21 -0.03 (-0.05%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more. MBX Biosciences beat analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.63 versus the -$0.73 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market OpensConference Call4:00 PM ET MBX Biosciences EPS ResultsActual EPS-$0.63Consensus EPS -$0.73Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersMBX Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) MBX Biosciences Q3 2025 Earnings FAQ Did MBX Biosciences beat earnings estimates for Q3 2025? MBX Biosciences (NASDAQ:MBX) reported earnings of -$0.63 per share for Q3 2025, beating the consensus estimate of -$0.73. The report was announced on Thursday, November 6, 2025. MBX Biosciences Earnings HeadlinesMBX Biosciences (NASDAQ:MBX) Stock Price Target Raised at Stifel Nicolaus4 hours ago | americanbankingnews.comMBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Consensus Target Price of $83.89 According to BrokeragesOctober 12 at 2:44 AM | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 12 at 1:00 AM | Awesomely (Ad)Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?October 10 at 10:12 AM | finance.yahoo.comMBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%October 9 at 11:49 PM | finance.yahoo.comMBX Biosciences出席Stifel心臟代謝論壇：管線佈局押注給藥優勢September 30, 2026 | hk.investing.comSee More MBX Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MBX Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MBX Biosciences and other key companies, straight to your email. Email Address About MBX BiosciencesMBX Biosciences (NASDAQ:MBX) is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Endocrine Peptide platform to design engineered peptides intended to provide targeted activity, extended duration and more consistent treatment effects. MBX’s lead program, MBX 1416, is an investigational long-acting parathyroid hormone receptor agonist being developed as a potential replacement therapy for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone. The company’s broader pipeline is focused on additional peptide-based medicines for endocrine diseases with significant unmet treatment needs. Headquartered in Indianapolis, Indiana, MBX Biosciences is advancing its programs through clinical development and regulatory evaluation. Its therapies are intended for patients in markets where endocrine disorders are treated with approved pharmaceutical products, although specific commercial geographies will depend on future clinical results and regulatory authorizations.View MBX Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
